Cantor Fitzgerald Lifts Target on Celgene (CELG) to $96 on ABRAXANE

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Cantor Fitzgerald Lifts Target on Celgene (CELG) to $96 on ABRAXANE

Celgene (CELG) Reports ABRAXANE Phase III Met Primary Endpoint in Adv. Pancreatic Cancer

November 9, 2012 5:02 PM EST

Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III study of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically... More